Comparative Effectiveness of Multiple Different First-Line Treatment Regimens for Helicobacter pylori Infection: A Network Meta-analysis

Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line Helicobacter pylori treatment: a multicentre randomised trial in Japan

(2020) Sho Suzuki et al.   GUT

Screening and eradication of Helicobacter pylori for gastric cancer prevention: the Taipei global consensus

(2020) Jyh-Ming Liou et al.   GUT

European Registry on Helicobacter pylori management (Hp-EuReg): patterns and trends in first-line empirical eradication prescription and outcomes of 5 years and 21 533 patients

(2020) Olga P Nyssen et al.   GUT

Vonoprazan‐containing Helicobacter pylori triple therapies contribution to global antimicrobial resistance

(2020) David Y Graham et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Transitioning of Helicobacter pylori Therapy from Trial and Error to Antimicrobial Stewardship

(2020) David Y. Graham   Antibiotics-Basel

Randomised controlled trial: susceptibility-guided therapy versus empiric bismuth quadruple therapy for first-line Helicobacter pylori treatment

(2019) Qi Chen et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

A network meta-analysis of randomized controlled trials exploring the role of fecal microbiota transplantation in recurrent Clostridium difficile infection

(2019) Theodore Rokkas et al.   United European Gastroenterology Journal

Ten-day concomitant, 10-day sequential, and 7-day triple therapy in first-line treatment of Helicobacter pylori infection: a randomized nationwide trial in Korea

(2019) Beom Jin Kim et al.   Gut and Liver

Houston Consensus Conference on Testing for Helicobacter pylori Infection in the United States

(2018) Hashem B. El-Serag et al.   Clinical Gastroenterology and Hepatology

Prevalence of antibiotic resistance in Helicobacter pylori : a systematic review and meta-analysis in World Health Organization regions

(2018) Alessia Savoldi et al.   GASTROENTEROLOGY

Ten-day high-dose proton pump inhibitor triple therapy versus sequential therapy for Helicobacter pylori eradication

(2018) Chonticha Auesomwang et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Comparison of 10 and 14 days of triple therapy versus 10 days of sequential therapy for Helicobacter pylori eradication: A prospective randomized study

(2018) Abulgasim Ennkaa et al.   Turkish Journal of Gastroenterology

Vonoprazan- vs proton-pump inhibitor-based first-line 7-day triple therapy for clarithromycin-susceptible Helicobacter pylori : A multicenter, prospective, randomized trial

(2017) Soichiro Sue et al.   HELICOBACTER

Review: A Japanese population-based meta-analysis of vonoprazan versus PPI for Helicobacter pylori eradication therapy: Is superiority an illusion?

(2017) Shou Quan Dong et al.   HELICOBACTER

Helicobacter pylori infection and antibiotic resistance: a WHO high priority?

(2017) Bich N. Dang et al.   Nature Reviews Gastroenterology & Hepatology

Vonoprazan-Based Regimen Is More Useful than PPI-Based One as a First-LineHelicobacter pyloriEradication: A Randomized Controlled Trial

(2017) Masafumi Maruyama et al.   Canadian Journal of Gastroenterology and Hepatology

Comparison of sequential therapy and amoxicillin/tetracycline containing bismuth quadruple therapy for the first-line eradication of Helicobacter pylori: a prospective, multi-center, randomized clinical trial

(2016) Ju Yup Lee et al.   BMC GASTROENTEROLOGY

Randomized clinical trial comparing 10-day sequential, 7-day concomitant and 7-day standard triple therapies for Helicobacter pylori eradication

(2016) Bojan Tepeš et al.   EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY

Randomized clinical trial comparing ten day concomitant and sequential therapies for Helicobacter pylori eradication in a high clarithromycin resistance area

(2016) Sotirios D. Georgopoulos et al.   European Journal of Internal Medicine

Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy forHelicobacter pylorieradication: a phase III, randomised, double-blind study

(2016) Kazunari Murakami et al.   GUT

Management ofHelicobacter pyloriinfection—the Maastricht V/Florence Consensus Report

(2016) P Malfertheiner et al.   GUT

Sequential Therapy versus Triple Therapy for the First Line Treatment of Helicobacter pylori in Korea: A Nationwide Randomized Trial

(2016) Joon Sung Kim et al.   Gut and Liver

Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial

(2016) Jyh-Ming Liou et al.   LANCET

Review article: the global emergence ofHelicobacter pyloriantibiotic resistance

(2015) I. Thung et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations

(2015) Brian Hutton et al.   ANNALS OF INTERNAL MEDICINE

High-dose Dual Therapy Is Superior to Standard First-line or Rescue Therapy for Helicobacter pylori Infection

(2015) Jyh-Chin Yang et al.   Clinical Gastroenterology and Hepatology

Kyoto global consensus report onHelicobacter pylorigastritis

(2015) Kentaro Sugano et al.   GUT

Ten-day triple therapyversussequential therapyversusconcomitant therapy as first-line treatment forHelicobacter pyloriinfection

(2015) Tiing Leong Ang et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

A Randomized Controlled Study Comparing Reverse Hybrid Therapy and Standard Triple Therapy for Helicobacter pylori Infection

(2015) Ping-I Hsu et al.   MEDICINE

Seven-Day Nonbismuth Containing Quadruple Therapy Could Achieve a Grade “A” Success Rate for First-LineHelicobacter pyloriEradication

(2015) Wei-Chen Tai et al.   Biomed Research International

The association between Helicobacter pylori infection and inflammatory bowel disease based on meta-analysis

(2015) T Rokkas et al.   United European Gastroenterology Journal

Randomized Controlled Trial Comparing 7-Day Triple, 10-Day Sequential, and 7-Day Concomitant Therapies for Helicobacter pylori Infection

(2014) Ping-I Hsu et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

A randomised clinical trial of 10-day concomitant therapy and standard triple therapy for Helicobacter pylori eradication

(2014) Jun Heo et al.   DIGESTIVE AND LIVER DISEASE

Sequential Therapy for 10 Days Versus Triple Therapy for 14 Days in the First-line Treatment of Helicobacter pylori Infection— A Multicenter, Open-label, Randomized Trial

(2013) Jyh-Ming Liou et al.   Clinical Gastroenterology and Hepatology

Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a prospective randomized study

(2013) Hassan Seddik et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Graphical Tools for Network Meta-Analysis in STATA

(2013) Anna Chaimani et al.   PLoS One

Penbactam for Helicobacter pylori eradication: A randomised comparison of quadruple and triple treatment schedules in an Iranian population

(2013) Seyedali Seyedmajidi et al.   Arab Journal of Gastroenterology

Helicobacter pyloriresistance to antibiotics in Europe and its relationship to antibiotic consumption

(2012) Francis Megraud et al.   GUT

Levofloxacin-containing Triple and Sequential Therapy or Standard Sequential Therapy as the First Line Treatment forHelicobacter pyloriEradication in China

(2012) Juan Qian et al.   HELICOBACTER

Ten-day sequentialversustriple therapy forHelicobacter pylorieradication: A prospective, open-label, randomized trial

(2012) Jun-Won Chung et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: Result of the HPFEZ randomised study

(2012) Mounia Lahbabi et al.   Clinics and Research in Hepatology and Gastroenterology

Randomised clinical trial: the efficacy of a 10-day sequential therapy vs. a 14-day standard proton pump inhibitor-based triple therapy for Helicobacter pylori in Korea

(2011) Y. S. Kim et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Randomised clinical trial: comparative study of 10-day sequential therapy with 7-day standard triple therapy for Helicobacter pylori infection in naïve patients

(2011) H. G. Park et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Review article: the effectiveness of standard triple therapy for Helicobacter pylori has not changed over the last decade, but it is not good enough

(2011) J. P. Gisbert et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Effectiveness of three times daily lansoprazole/amoxicillin dual therapy for Helicobacter pylori infection in Korea

(2011) Seung Young Kim et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Comparison of levofloxacin-containing sequential and standard triple therapies for the eradication of Helicobacter pylori

(2011) Zulfikar Polat et al.   European Journal of Internal Medicine

Ten-day sequential therapy is more effective than proton pump inhibitor-based therapy in Korea: A prospective, randomized study

(2011) Hong Sang Oh et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Efficacy of Levofloxacin and Rifaximin based Quadruple Therapy in Helicobacter pylori Associated Gastroduodenal Disease: A Double-Blind, Randomized Controlled Trial

(2011) Kang Hyun Choi et al.   JOURNAL OF KOREAN MEDICAL SCIENCE

14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial

(2011) E Robert Greenberg et al.   LANCET

Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial

(2011) Peter Malfertheiner et al.   LANCET

Efficacy and safety of Levofloxacin, Clarithromycin and Esomeprazol as first line triple therapy for Helicobacter pylori eradication in Middle East. Prospective, randomized, blind, comparative, multicenter study

(2010) M. Assem et al.   European Journal of Internal Medicine

Empirical levofloxacin-containing versus clarithromycin-containing sequential therapy for Helicobacter pylori eradication: a randomised trial

(2010) M. Romano et al.   GUT

Levofloxacin-based and clarithromycin-based triple therapies as first-line and second-line treatments for Helicobacter pylori infection: a randomised comparative trial with crossover design

(2010) J. M. Liou et al.   GUT

Helicobacter pylori treatment in the era of increasing antibiotic resistance

(2010) D. Y. Graham et al.   GUT

Comparison of the once-daily levofloxacin-containing triple therapy with the twice-daily standard triple therapy for first-line Helicobacter pylori eradication: a prospective randomised study

(2010) L.-W. Chen et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial

(2010) Georgia Salanti et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

Ten and Eight-day Sequential Therapy in Comparison to Standard Triple Therapy for Eradicating Helicobacter pylori Infection

(2010) Omero Alessandro Paoluzi et al.   JOURNAL OF CLINICAL GASTROENTEROLOGY

Standard triple, bismuth pectin quadruple and sequential therapies forHelicobacter pylorieradication

(2010) Xiao-Zhong Gao   WORLD JOURNAL OF GASTROENTEROLOGY

Triple or Quadruple Tetracycline-Based Therapies Versus Standard Triple Treatment for Helicobacter pylori Treatment

(2009) Yildiran Songür et al.   AMERICAN JOURNAL OF THE MEDICAL SCIENCES

Clarithromycin-Amoxycillin-Containing Triple Therapy: A Valid Empirical First-Line Treatment forHelicobacter pyloriEradication in Hong Kong?

(2009) Ivan F.N. Hung et al.   HELICOBACTER